Tianjin Pharmaceutical Da Ren Tang (SGX:T14) estimated a net profit attributable to equity holders for the first six months of the year to range between 1.84 billion yuan to 2.0 billion yuan, according to a filing with the Singapore Exchange on Monday.
The increase will represent a 180% to 204% year over year.
The company has attributed this to the disposal of its remaining stake in Tianjin TSKF Pharmaceutical to Haleon China and Haleon CH SARL for around 1.54 billion yuan.
Shares of the company were up nearly 1% in recent trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。